Bellerophon Therapeutics, Inc. BLPH
Day range unavailable
52-week range unavailable
- Market cap
- 7.91M
- Revenue (ttm)
- 5.64M
- Profit margin
- -201.56%
- Shares out
- 10.45M
- Forward P/E
- -0.45
- Beta
- 0.60
- Analysts
- Buy
- Price target
- 2.00 (+16566.7%)
- Earnings date
- Dec 17, 2024
2Y -0.7980 (-98.52%)
Key statistics
- Enterprise value
- -8.12M
- PEG ratio
- 0.00
- Price / sales
- 1.40
- Price / book
- 0.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -8.17M
- Total cash
- 15.17M
- Total debt
- 8.00K
- Return on equity
- -84.92%
- Short % of float
- 5.35%
- 50-day average
- 4.34
- 200-day average
- 3.45
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 17, 2024
Expected Dec 17, 2024. Consensus EPS estimate -0.40.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 17, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 1, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 6, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 6, 2023 | Laidlaw & Co. | down | Buy | Hold |
| May 9, 2023 | Laidlaw & Co. | init | — | Buy |
| Apr 4, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Nov 25, 2020 | Jefferies | init | — | Buy |
| Nov 25, 2020 | Maxim Group | init | — | Buy |
About Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bellerophon.com
News
12 Health Care Stocks Moving In Friday's Intraday Session 
Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Friday
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Dow Surges 50 Points; General Electric Profit Tops Expectations - Nasdaq Rises 70 Points; General Motors Posts Upbeat Earnings
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?
Your note
Sign in to keep a note on BLPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMIN NASEEM M.D. | Director | Stock Award(Grant) | Jun 6, 2023 | 291,865 |
| DEKKER MARTIN | Officer | Conversion of Exercise of derivative security | Dec 8, 2022 | 17,666 |
| FERNANDES PETER | Officer | Conversion of Exercise of derivative security | Dec 8, 2022 | 22,515 |
| KIM BOBAE | Officer | Sale | May 17, 2023 | 1,723 |
| LACCONA NICHOLAS | Chief Financial Officer | Conversion of Exercise of derivative security | Dec 8, 2022 | 12,470 |
| NEW MOUNTAIN INVESTMENTS II L L C | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 17, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 8.90% | 930,000 | 703.54K | Mar 30, 2023 |
| Morgan Stanley | 8.63% | 901,467 | 681.96K | Mar 30, 2023 |
| Tang Capital Management, LLC | 8.55% | 893,974 | 676.29K | Mar 30, 2023 |
| Wells Fargo & Company | 1.91% | 200,066 | 151.35K | Mar 30, 2023 |
| Renaissance Technologies, LLC | 1.63% | 169,899 | 128.53K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 1.40% | 145,810 | 110.31K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.36% | 142,168 | 107.55K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.37% | 38,218 | 28.91K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.09% | 9,250 | 7.00K | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.07% | 7,640 | 5.78K | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 4,969 | 3.76K | Feb 27, 2023 |
| Dimensional ETF Tr-Dimensional U.S. Core Equity 2 ETF | 0.04% | 4,517 | 3.42K | Jan 30, 2023 |